Erlotinib hydrochloride is the hydrochloride salt of erlotinib, an oral, first-generation, reversible tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR), used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) and pancreatic cancer.